Discover the SUNSCAPE Studies, a study program for people affected by moderate to severe UC
The SUNSCAPE Studies are clinical trials evaluating the effectiveness and safety of an investigational drug to see if it can treat moderately to severely active ulcerative colitis (UC).
The studies include several parts. In SUNSCAPE-1, you may receive the investigational study drug or a placebo for 12 to 24 weeks. Depending on your response, you may qualify to move on to SUNSCAPE-2, a maintenance part for 40 weeks. At the end, everyone may join the open-labeled extension part and continue receiving the investigational study drug.
Are 18 years or older (or at least 16 in some countries).
Have been diagnosed with moderate to severe UC at least 3 months ago that is currently active.
Have frequent bowel movements with visible bleeding.
Have not responded well to previous UC treatments or could not tolerate them.
Are willing to follow all study procedures: site visits, colonoscopies, and symptom tracking.
Dr. Call, co-founder of Clinical Research Partners, serves as President. He is a Certified Principle Investigator
Annette Bennett, co-founder of Clinical Research Partners, serves as Chief Executive Officer and Research Director. She
Bo Vaughan is a native of Richmond, VA and forward-thinking health care strategist with a
